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Aim: To evaluate the effect of lymphadenectomy and/or radiotherapy on recurrence and sur-
vival patterns in endometrial carcinoma (EC) in a radiotherapy reference centre population.
Material and Methods: A retrospective population-based review was conducted on 261
patients with stages I–III EC. Univariate and multivariate analyses were carried out. Both
recurrence and survival were analysed according to patient age, FIGO stage, tumour size,
myometrial invasion, tumour grade, lymphadenectomy, external beam irradiation (EBI), and
brachytherapy (BT).
Results: Median age: 64.8 years. Median follow-up: 151 months. The following treat-
ments were administered: surgery, 97.32%; lymph-node dissection, 54.4%; radiotherapy, 162
patients (62%) (EBI and BT: 64.1%, BT alone: 30.2%, EBI alone: 5.6%).Lymphadenectomy Twenty-six patients (9.96%) suffered loco-regional recurrence, whilst 27 (10.34%) suffered
distant failure. The 5-year overall survival (OS) for all stages was 80.1%. The 5-year disease
free  survival (DFS) was 92.1% for all patients. The 10-year DFS was 89.9%.
The independent signiﬁcant prognostic factors for a good outcome identiﬁed through the
multivariate analysis were: age <75 years (p = 0.001); tumour size ≤2 cm (p = 0.003); myome-
trial  invasion ≤50% (p = 0.011); lymphadenectomy (p = 0.02); EBI (p = 0.001); and BT (p = 0.031).
∗ Corresponding author at: Radiation Oncology Department, Hospital Universitari Sant Joan de Reus, C/Sant Joan, s/n, Reus, Tarragona,
Spain.  Tel.: +34 682293209.
E-mail addresses: marenas@grupsagessa.com, meritxell.arenas@gmail.com (M. Arenas).
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Toxicity occurred in 114 of the 162 patients who received radiotherapy (70.5%). The toxicity
was  mainly acute, and late in only 28.3% (n = 45) of cases. The majority experienced G1-2
toxicity, and only 3% of patients experienced G3 late toxicity (5/162).
Conclusions: Our results suggest that age <75 years, tumour size ≤2 cm, myometrial invasion
≤50%, lymphadenectomy, EBI, and BT, are predictors of a good outcome in EC.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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t.  Background
ndometrial carcinoma (EC) is the third most common cancer
iagnosed in women and the most common female genital
ract malignancy. The incidence of EC in Catalonia (Spain) is
30 new cases per year. EC represents 6.1% of newly diagnosed
ancers in women.1,2
Treatment of EC is mainly surgical and consists of
 total abdominal hysterectomy and a bilateral salpingo-
ophorectomy (TAH & BSO), with or without pelvic lymph
ode dissection, followed by postoperative radiotherapy (RT)
n most cases. Surgical staging requires the expertise of
 gynaecological oncologist in a tertiary care centre. The
eed for lymphadenectomy remains a point of controversy.
ome studies have conﬁrmed that lymphadenectomy can be
oth diagnostic and therapeutic, and that it allows for more
daptable postoperative RT; others have concluded that there
s no evidence of any beneﬁt in terms of overall survival
OS).3–7 However, many  studies have conﬁrmed advantages to
ymphadenectomy such as: reduced complexity8; increased
ccuracy of magnetic resonance imaging (MRI) in pre-
perative staging9; and better prognostics.10,11
Prospective randomised studies have shown that RT
educes the risk of pelvic relapse but does not improve OS
n patients with early EC.12–14 The Postoperative Radiothe-
apy Endometrial Cancer (PORTEC-2) study demonstrated that
atients with intermediate-risk EC can be safely treated with
rachytherapy (BT) alone.15
The decision to offer adjuvant pelvic radiation depends
n the type of surgery undertaken, as well as the primary
umour risk factors. In intermediate-risk groups, pelvic radia-
ion may be offered if the patient exhibits adverse prognostic
actors. The risk of metastatic pelvic nodes increases in high-
isk groups, and therefore, pelvic RT is often offered.16–21
Despite the fact that postoperative external beam pelvic
T is offered to minimise the risk of recurrence in case of
oor prognostic factors, severe late complications have been
eported, occurring mainly in the small bowel, in 3–8% of cases
reated with external beam pelvic RT.14–22
The Radiation Department at the Hospital Universitari de
ant Joan de Reus is the only referral RT centre in Tarragona
rovince and receives patients from 7 hospitals performing
ynaecological cancer surgery..  Aim
he aim of this retrospective study was to determine
he prognostic factors that contribute to patient outcomes,and to evaluate the roles and impact on survival of lym-
phadenectomy and/or RT in EC in this RT reference centre
population.
3.  Materials  and  methods
A retrospective population-based review was conducted on
261 patients with stages I–III EC (excluding sarcoma cases) that
were treated in one Radiation Oncology Institution after refer-
ral from seven different gynaecology departments during the
period 1997 to 2006.
Information regarding patients, disease, and treatment
characteristics were retrospectively collected from the patient
records. After surgery, the patients were staged accord-
ing to the International Federation of Gynaecology and
Obstetrics (FIGO-1992). The surgical procedure, pathologic
characteristics of the tumour, RT, chemotherapy, and distance
travelled by patients from their home to our centre were
recorded.
The lymphadenectomy policies varied among the different
centres, but in general it was offered to high risk of recur-
rence patients. Our institution’s protocol during the treatment
period (1997–2006) indicated an adjuvant postoperative exter-
nal beam RT to the pelvis without lymphadenectomy for
women with disease stage IB grade 2, stage IB grade 3, all
grades of stage IC, and all higher stages. Postoperative adju-
vant RT consisted of external beam pelvic radiation, vaginal
BT, or both. The time between surgery and RT treatment did
not exceed 4 weeks.
Clinical, surgical and pathological data were considered
when planning 3D conformal radiotherapy planning treat-
ment. The majority of patients were treated with 6 or 18 MV
from a Linac ray (66% of patients), or a 60-cobalt machine
(33% of patients) using the pelvic four-ﬁeld technique. The
total planned dose was 46–50 Gy at 180–200 cGy per fraction,
5 fractions/week. BT was administered using the Fletcher col-
postats technique for low-dose rate (LDR) 137Cs sources from
a Selectron, or using a vaginal cylinder applicator in one or
three treatments with a high-dose rate (HDR). After external
beam irradiation (EBI), the usual BT plan involved 20 Gy for LDR
treatments and 3 fractions of 4 Gy for HDR treatments. When
only BT was performed, the dose was 60 Gy for LDR  treatments
and 3 fractions of 7 Gy for HDR treatments. All BT doses were
prescribed for 5 mm inside the vaginal surface.
After the completion of the RT, a radiation oncologist rou-
tinely monitored women every 3–4 months for 2 years, and
every 6 months thereafter.
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Table 1 – Stage and pathologic characteristics of all
patients.
N (%)
FIGO stage
I 175 (67%)
II 47 (18%)
III 39 (15%)
Histological type
Endometrioid adenocarcinoma 195 (74.7%)
Papillary – serous 19 (7.3%)
Clear-cell 10 (3.8%)
Other 37 (14.2%)
Pathological grade
I 104 (39.8%)
II 108 (41.4%)
III 49 (18.8%)
Tumour size (cm)
≤2 cm 224 (85%)
>2 cm 37 (14.2%)
Myometrial invasion
Table 2 – Treatment performed on all patients.
N (%)
Surgery 256 (98%)
Abdominal HT&DA 229 (87.7%)
Vaginal HT&DA 32 (12.3%)
Lymph node dissection 142 (54.4%)
Pelvic 85 (32.6%)
Pelvic + paraortic 53 (20.3%)
Paraortic alone 4  (1.5%)
Mean number pelvic lymph nodes 14 (2–47)
Mean number paraortic lymph nodes 7 (1–14)
Radiation treatment 162 (62%)
EBI and BT 104 (64.1%)
BT alone 49 (30.2%)
EBI alone 9 (5.6%)
Chemotherapy 11.51%
Hormonal therapy 6.3%
HT&DA: hysterectomy and bilateral salpingo-oophorectomy; EBI:
external beam irradiation; BT: brachytherapy.
outcome from multivariate analysis were: age <75 yearsNo invasion 21 (8%)
>50% 112 (43%)
<50% 128 (49%)
3.1.  Statistical  analysis
We  evaluated OS, disease-free survival (DFS), and loco-
regional free-survival (LRFS). The results were analysed using
SPSS, and statistical comparisons (OS, DFS and LFRS rates)
were carried out using the log-rank test. Univariate and
multivariate analyses of the corresponding variables were
undertaken for the OS, DFS and LFRS endpoints, including
analyses of lymphadenectomy, RT, and prognostic factors for
survival such as age, tumour size, and myometrial invasion.
Univariate analysis was undertaken using the chi-square test.
Multivariate analyses were undertaken using the Cox propor-
tional hazards model. A  value <0.05 was considered to be
signiﬁcant.
4.  Results
The mean patient age was 64.8 years (range 38–88). The mean
follow-up time was 151 months. 85% percent of the patients
lived within 70 km of the oncology centre, whilst 15% lived
over 70 km away.
The stage and pathologic characteristics of the samples are
shown in Table 1.
The treatments that were performed are described in
Table 2. The mean dose for external beam RT was 48.6 ± 6 Gy,
prescribed at the isocentre. The mean number of pelvic lymph
nodes removed was 14 (2–47), and a mean of 7 (1–14) paraortic
lymph nodes were removed.
Patient’s characteristics according to the lymphadenec-
tomy or RT treatment are shown in Table 3.
Relapses: 26 of the 261 patients (9.96%) suffered loco-
regional recurrence. The recurrence rates for stages I, II
and III were 9.26%, 4.65% and 13.89% respectively. 27 of
the 261 patients (10.34%) suffered distant failure, with pul-
monary metastases occurring most frequently. Recurrences
were treated with surgery ± RT ± chemotherapy ± hormonal
treatment.5 and 10-year survival (Fig. 1): The 5 and 10-year OS for
all stages was 80.1% and 65.6% respectively (Fig. 1A). The 5
and 10-year OS for stage I was 84% and 68.2% respectively;
90.3% and 78.4% respectively for stage II; and 64.5% and 52.4%
respectively for stage III. There was a statistically signiﬁcant
difference in OS between stages I/II versus III (84% vs. 64.5%;
p = 0.0016). The 5 and 10-year DFS was 92.1% and 89.9% for all
patients respectively (Fig. 1B). The 5 and 10-year DFS for stages
I was 93.5% and 89.1% respectively; 97.5% and 93.9% respec-
tively for stage II; and 79.8% and 89.4% respectively for stage
III. No differences were found in DFS between stages I/II versus
III.
The observed 5 and 10-year OS rates in patients that
received lymphadenectomy were 86% and 77.7% respectively,
and were 78.4% and 54.2% respectively for those who  did not
receive a lymphadenectomy (HR 2.821, 95% conﬁdence inter-
val (CI) 1.566–5.080; p = 0.020) (Fig. 2A). There was a signiﬁcant
difference in the survival curves for these two  groups (p = 0.000,
log-rank test). The 5 and 10-year DFS was 93.5% and 91.5% for
lymphadenectomy vs. no lymphadenectomy being performed
(p = 0.462, log-rank test) (Fig. 2B).
No differences were observed in 5 and 10-year OS with
respect to RT administration (p = 0.527, log-rank test) (Fig. 3A),
and the 5 and 10-year DFS was the same (92.1%) in both cases
(RT and non-RT groups) (p = 0.795, log-rank test) (Fig. 3B).
4.1.  Prognostic  factors
Univariate analyses revealed the following signiﬁcant progno-
stic factors of a good outcome: age <75 years (p = 0.000); FIGO
stage (I–II vs. IIII, p = 0.026); tumour size ≤2 cm (p = 0.003); grade
of differentiation (grade I and II vs. III, p = 0.007); myometrial
invasion <50% (p = 0.000); and BT (p = 0.000).
The independent signiﬁcant prognostic factors of a good(p = 0.001); tumour size ≤2 cm (p = 0.003); myometrial invasion
≤50% (p = 0.011); lymphadenectomy (p = 0.02); RT (p = 0.001);
and BT (p = 0.031).
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Table 3 – Patient’s characteristics according to the lymphadenectomy or radiotherapy treatment.
N (%)
Lymphadenectomy Radiotherapy
No Yes No Yes
Median age (years) 66.4 61.4 63.9 64
FIGO stage
I 79 (66.4%) 96 (67.6%) 85 (85.9%) 90 (55.6%)
II 25 (21%) 22 (15.5%) 8 (8%) 39 (24%)
III 15 (12.5%) 24 (16.9%) 6 (5%) 33 (20.4%)
Histological type
Adenocarcinoma 78 (65.6%) 117 (82.4%) 70 (70.7%) 125 (77.2%)
Papillary – serous 10 (8.4%) 9 (6.3%) 9 (9%) 10 (6.2%)
Clear-cell 4 (3.4%) 6 (4.2%) 10 (10.1%) 17 (10.5%)
Other 27 (22.7%) 10 (7%) 10 (10.1%) 10 (6.2%)
Pathological grade
I 49 (41.2%) 55 (38.7%) 44 (44.4%) 60 (37%)
II 55 (46.2%) 53 (37.3%) 45 (45.6%) 63 (38.9%)
III 15 (12.6%) 34 (23.9%) 10 (10%) 39 (24%)
Myometrial invasion
No invasion 11 (9.2%) 10 (7%) 9 (9%) 12 (7.4%)
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.2.  Differences  according  to  gynaecological  practice
Table  4)
here was a large variation in treatment practicesacross
arragona province, mainly in the lymphadenectomy per-
entages among the referring gynaecology units (chi-square
est, p = 0.000, range 24–85.71%). This data did not translate
nto 5-year OS or DFS differences in the multivariate analysis
HR 1.000, 95% conﬁdence interval (CI) 0.880–1.138; p = 0.994).
hen we  performed the analysis based on treatments, no
Table 4 – Treatment characteristics in the different surgical hos
Hospital Number of patients Stages 
N (%) 
A 80 I:  50 (62.5%)
II: 20 (25%)
III: 10 (12.5%)
B 45 I:  35 (77.8%)
II: 4 (8.9%)
III: 6 (13.3%)
C 36 I: 24 (66.7%)
II: 7 (19.4%)
III: 5 (13.9%)
D 36 I: 21 (58.3%)
II: 6 (16.7%)
III: 9 (25%)
E 14 I:  12 (85.7%)
II: 0%
III: 2 (14.3%)
F 16 I: 9 (56.3%)
II: 4 (25%)
III: 3 (18.8%)
G 33 I: 25 (75.8%)
II: 4 (12.1%)
III: 4 (12.1%)5.2%) 60 (60.6%) 52 (32%)
7.7%) 30 (30.3%) 98 (60.5%)
signiﬁcant improvement in OS and DFS was observed when RT
was administered to the patients without a lymphadenectomy
(p = 0.099 and p = 0.612 for OS and DFS respectively).
4.3.  RT  toxicityWe  evaluated acute and late toxicity based on both the
RTOG and LENT-SOMA scoring systems. All patients tolerated
irradiation without interruption of their treatment. Toxicity
occurred in 114 patients of the 162 patients that received RT
pitals.
Lymphadenectomy Radiotherapy
N (%) N (%)
43 (53.7%) 49 (61.3%)
27 (60%) 19 (42.2%)
31 (86.1%) 21 (58.3%)
17 (47.2%) 32 (88.9%)
6  (42.9%) 11 (78.6%)
8  (50%) 10 (62.5%)
8  (24.2%) 19 (57.6%)
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Fig. 1 – Overall survival (OS) (A) and disease-free survival
(DFS) (B) in all patients.
Fig. 2 – Overall survival (OS) (A) and disease-free survival
(DFS) (B) in patients that did and did not receive
lymphadenectomy.
invasion (deﬁned as invasion of the outer third of the myome-(70.5%), and the remaining 48 patients (29.5%) did not suffer
any toxicity. It was mainly acute toxicity, with late toxicity
occurring in only 28.3% (n = 45) of cases. The majority of them
experienced G1-2 toxicity (70%). Acute G3-4 toxicity appeared
in 4.3% (7/162) (5 patients experienced G3 gastrointestinal tox-
icity, 1 patient experienced G3 bladder toxicity, and 1 patient
experienced G4 gastrointestinal toxicity) and G3-4 late toxic-
ity appeared in 3% (5/162) of patients (3 cases in the colon and
small intestine, 1 case with rectal toxicity, and 1 with bladder
toxicity). A Co-60 treatment was administered in 11 of 12 cases
with grade 3 and 4 toxicity (acute and late toxicity).
5.  DiscussionThis study was performed to retrospectively evaluate
population-based results in 261 cases of EC in Tarragona,Spain. Different parameters were analysed in this study in
order to determine their inﬂuence on recurrence and survival.
We found that classical prognostic factors such as
advanced age, stage, tumour size, deep myometrial invasion,
and high grades, predict lower OS and DFS rates, supporting
similar reports in the literature.14,23–25 We analysed the impact
of lymphadenectomy and RT on OS and DFS.
Different studies have demonstrated that patients with
stage I EC have 5-year OS rates of 80–90%, and 5-year cancer-
speciﬁc survival rates of 90–95%.13,26–29 In our study, the OS
and the DFS for stage I was 84% and 93.5% respectively. Other
authors have reported that patient cohorts with high-grade
tumours and deep myometrial invasion (>50%) have a signif-
icantly higher risk of both locoregional and distant relapse.25
The Gynaecologic Oncology Group (GOG) study24 revealed that
microscopic pelvic nodal metastases were present in 18% of
patients with clinical stage I tumours and deep myometrialtrial wall), compared to their presence in under 10% of the
remaining population.
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RT toxicity in our study was similar to RT toxicity reported
n other studies. Grade 3 and 4 late complications were seen
n 3% of cases treated with EBI, and there was only one case of
rade 4. The majority of patients with grade 3 and 4 compli-
ations were treated with Co-60 machine. These results were
imilar to those reported in other studies.13 Reduction of rec-
al volume has been associated with lower rectal dose-volume
arameters that could be a step in the reduction of toxicity.30
Lymphadenectomy is one of the controversial aspects of
he surgical treatment of EC. More  than half of our patients
54.4%) had lymphadenectomy, and a signiﬁcant improvement
n 5 and 10-year OS was observed in this group of patients
n univariate analysis, but signiﬁcance was lost in multivari-
te analysis. It appears to be useful in high-risk patients, and
ould be avoided in low-risk patients. More  studies are there-
ore needed to answer these questions in more  depth.31The impact of RT was the remaining aspect of our study.
he role of radiation therapy in EC has been investigated
sing randomised and retrospective series, and remainsiotherapy 2 0 ( 2 0 1 5 ) 50–56 55
controversial in some stages.12–14,32,33 The randomised trial
results reported by Aalders et al. revealed that the addition
of EBI after TAH & BSO and vaginal BT led to reduced vagi-
nal and pelvic recurrence rates, even though no statistically
signiﬁcant survival beneﬁt was observed (5-year survival rate,
89% vs. 91%).12 This study also suggested a survival beneﬁt for
the patient subgroup with grade 3 tumours and deep (stage IC)
myometrial invasion. The PORTEC-1 trial demonstrated a sig-
niﬁcant locoregional beneﬁt with RT, and postoperative pelvic
RT was indicated for patients over the age of 60, those with
grade 3 EC, or those with grade 1–2 EC with >50% myometrial
invasion.13,23 A phase III trial published by GOG demonstrated
that postoperative pelvic RT signiﬁcantly reduced the risk of
recurrence in intermediate-risk patients, and that pelvic RT
was recommended for patients in the high intermediate-risk
category (grade 2–3 tumours with lymphovascular invasion
and outer third myometrial invasion), patients over 50 years
old with any of the 2 previously mentioned risk factors, and
patients over 70 years old with any of the previously listed risk
factors.14
The PORTEC-2 trial revealed that BT should be the adju-
vant treatment of choice for patients with EC in the high
intermediate-risk category.15
The PORTEC-3 study will clarify whether high-risk patients
need external beam RT in addition to chemotherapy.
In our study, postoperative radiotherapy was administered
to 62% (EBI and BT: 64.1%, BT alone: 30.2%, EBI alone: 5.6%)
of patients, neither of which had an impact on 5 and 10-
year OS and DFS (p = 0.527 and p = 0.795, respectively, log-rank
test). In our study, the surgical centres that performed fewer
lymphadenectomies referred patients for postoperative treat-
ments more  frequently; this may be a reason why the survival
rates are similar and no signiﬁcant differences in OS among
the different surgical units were observed.
Despite clinical guides the usual practice shows large dif-
ference on lymphadenectomy numbers among centres and
this has no impact on OS. Then we could hypothesise that RT
could improve and homogenise outcomes of surgically treated
EC.
Future analyses are necessary to clarify the role of sys-
tematic lymphadenectomy in EC, and to determine whether
postoperative RT could be avoided in early stage EC.
6.  Conclusion
Our results suggest that the predictors of a good outcome
were: an older age, tumour size ≤2 cm,  myometrial invasion
≤50%, as well as lymphadenectomy, EBI, and BT, in our popu-
lation series with EC.
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